Skip to main content
Erschienen in:

29.06.2016 | Lungenkarzinome | CME

Kleinzelliges Lungenkarzinom

verfasst von: PD Dr. med. M. B. Steins, C. Henkenberens, M. Bremer, M. Thomas

Erschienen in: Die Onkologie | Ausgabe 10/2016

Einloggen, um Zugang zu erhalten

Zusammenfassung

Hintergrund

Prognostische Verbesserungen für Patienten mit einem kleinzelligen Lungenkarzinom (SCLC) konnten in der letzten Dekade insbesondere durch den Einsatz radiotherapeutischer Behandlungsansätze erreicht werden.

Methodik

Dieser Beitrag vermittelt einen Überblick über die bewährten sowie auch aktualisierten Therapieelemente in der Behandlung des SCLC.

Ergebnisse

Angesichts des hohen Proliferations- und Metastasierungspotenzials des SCLC stellt die systemische Chemotherapie, vorzugsweise in Form einer Platin-Etoposid-Kombination, weiterhin die therapeutische Grundlage dar. Im limitierten Stadium wird diese möglichst simultan mit einer thorakalen Radiotherapie (TRT), gefolgt von einer prophylaktischen Ganzhirnbestrahlung (PCI) durchgeführt. Auch im extendierten Stadium (ED) kommt der TRT bei auf die Chemotherapie ansprechenden Patienten ein therapeutischer Stellenwert zu. Eine PCI reduziert zwar grundsätzlich das zerebrale Metastasierungsrisiko, wird aber in Hinsicht auf eine Verbesserung des Gesamtüberlebens beim ED-Stadium kontrovers diskutiert.

Schlussfolgerung

Neben der Chemotherapie ist v. a. die Radioonkologie für das Überleben der von einem SCLC betroffenen Patienten von entscheidender Bedeutung.
Literatur
1.
Zurück zum Zitat Goeckenjan G, Sitter H, Thomas M et al (2011) Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms. Interdisziplinäre S3-Leitlinie der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin und der Deutschen Krebsgesellschaft. Pneumologie 65:39–59CrossRefPubMed Goeckenjan G, Sitter H, Thomas M et al (2011) Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms. Interdisziplinäre S3-Leitlinie der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin und der Deutschen Krebsgesellschaft. Pneumologie 65:39–59CrossRefPubMed
2.
Zurück zum Zitat Früh M, De Ruysscher D, Popat S et al (2013) Small-cell lung cancer (SCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 6:99–105 Früh M, De Ruysscher D, Popat S et al (2013) Small-cell lung cancer (SCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 6:99–105
3.
Zurück zum Zitat Rivera P, Mehta AC (2007) Initial diagnosis of lung cancer. ACCP evidence-based clinical practice guidelines. Chest 132:131–148SCrossRef Rivera P, Mehta AC (2007) Initial diagnosis of lung cancer. ACCP evidence-based clinical practice guidelines. Chest 132:131–148SCrossRef
4.
Zurück zum Zitat Ebert W, Muley T, Drings P (1996) Does the assessment of serum markers in patients with lung cancer aid in the clinical decision making process? Anticancer Res 16:2161–2168PubMed Ebert W, Muley T, Drings P (1996) Does the assessment of serum markers in patients with lung cancer aid in the clinical decision making process? Anticancer Res 16:2161–2168PubMed
5.
Zurück zum Zitat Gandhi L, Johnson BE (2006) Paraneoplastic syndromes associated with small cell lung cancer. J Natl Compr Canc Netw 4:631–638PubMed Gandhi L, Johnson BE (2006) Paraneoplastic syndromes associated with small cell lung cancer. J Natl Compr Canc Netw 4:631–638PubMed
6.
Zurück zum Zitat Quan A, Videtic GM, Suh JH (2004) Brain metastases in small cell lung cancer. Oncology 18:961–972PubMed Quan A, Videtic GM, Suh JH (2004) Brain metastases in small cell lung cancer. Oncology 18:961–972PubMed
7.
Zurück zum Zitat Karam I, Jiang SY, Khaira M et al (2015) Outcomes of small cell lung cancer patients treated with cisplatin-etoposide versus carboplatin-etoposide. Am J Clin Oncol 38:51–54CrossRefPubMed Karam I, Jiang SY, Khaira M et al (2015) Outcomes of small cell lung cancer patients treated with cisplatin-etoposide versus carboplatin-etoposide. Am J Clin Oncol 38:51–54CrossRefPubMed
8.
Zurück zum Zitat Noda K, Nishiwaki Y, Kawahara M et al (2002) Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 346:85–91CrossRefPubMed Noda K, Nishiwaki Y, Kawahara M et al (2002) Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 346:85–91CrossRefPubMed
9.
Zurück zum Zitat Hanna N, Bunn PA Jr, Langer C et al (2006) Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol 24:2038–2043CrossRefPubMed Hanna N, Bunn PA Jr, Langer C et al (2006) Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol 24:2038–2043CrossRefPubMed
10.
Zurück zum Zitat Lara PN Jr, Natale R, Crowley J et al (2009) Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol 27:2530–2535CrossRefPubMedPubMedCentral Lara PN Jr, Natale R, Crowley J et al (2009) Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol 27:2530–2535CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat O’Brien ME, Ciuleanu TE, Tsekov H et al (2006) Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol 24:5441–5447CrossRefPubMed O’Brien ME, Ciuleanu TE, Tsekov H et al (2006) Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol 24:5441–5447CrossRefPubMed
12.
Zurück zum Zitat Pawel J von, Schiller JH, Shepherd FA et al (1999) Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 17:658–667 Pawel J von, Schiller JH, Shepherd FA et al (1999) Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 17:658–667
13.
Zurück zum Zitat Eckardt JR, Pawel J von, Pujol JL et al (2007) Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. J Clin Oncol 25:2086–2092CrossRefPubMed Eckardt JR, Pawel J von, Pujol JL et al (2007) Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. J Clin Oncol 25:2086–2092CrossRefPubMed
14.
Zurück zum Zitat Huber RM, Gatzemeier U, Gosse H et al (2000) Topotecan in second-line therapy of SCLC: Impact on survival? Onkologie 23 (suppl 3):9–12 Huber RM, Gatzemeier U, Gosse H et al (2000) Topotecan in second-line therapy of SCLC: Impact on survival? Onkologie 23 (suppl 3):9–12
15.
Zurück zum Zitat Reck M, Haering B, Koschel G et al (1998) Chemotherapie des fortgeschrittenen nicht-kleinzelligen und kleinzelligen Bronchialkarzinoms mit Bendamustin – eine Phase II Studie. Pneumologie 52:571–574 Reck M, Haering B, Koschel G et al (1998) Chemotherapie des fortgeschrittenen nicht-kleinzelligen und kleinzelligen Bronchialkarzinoms mit Bendamustin – eine Phase II Studie. Pneumologie 52:571–574
16.
Zurück zum Zitat Ettinger DS, Finkelstein DM, Sarma RP, Johnson DH (1995) Phase II study of paclitaxel in patients with extensive-disease small-cell lung cancer: an eastern cooperative oncology group study. J Clin Oncol 13:1430–1435PubMed Ettinger DS, Finkelstein DM, Sarma RP, Johnson DH (1995) Phase II study of paclitaxel in patients with extensive-disease small-cell lung cancer: an eastern cooperative oncology group study. J Clin Oncol 13:1430–1435PubMed
17.
Zurück zum Zitat Al-Batran SE, Atmaca A, Bert F et al (2004) Dose escalation study for defining the maximum tolerated dose of continuous oral trofosfamide in pretreated patients with metastatic lung cancer. Onkologie 27:534–538PubMed Al-Batran SE, Atmaca A, Bert F et al (2004) Dose escalation study for defining the maximum tolerated dose of continuous oral trofosfamide in pretreated patients with metastatic lung cancer. Onkologie 27:534–538PubMed
18.
Zurück zum Zitat Pawel J von, Jotte R, Spigel DR et al (2014) Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer. J Clin Oncol 32:4012–4019CrossRef Pawel J von, Jotte R, Spigel DR et al (2014) Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer. J Clin Oncol 32:4012–4019CrossRef
19.
Zurück zum Zitat Rudin CM, Ismaila N, Hann CL et al (2015) Treatment of small-cell lung cancer: american society of clinical oncology endorsement of the american college of chest physicians guideline. J Clin Oncol 33:4106–4111CrossRefPubMed Rudin CM, Ismaila N, Hann CL et al (2015) Treatment of small-cell lung cancer: american society of clinical oncology endorsement of the american college of chest physicians guideline. J Clin Oncol 33:4106–4111CrossRefPubMed
20.
Zurück zum Zitat Corso CD, Rutter CE, Park HS et al (2015) Role of chemoradiotherapy in elderly patients with limited small-cell lung cancer. J Clin Oncol 33:4240–4246CrossRefPubMedPubMedCentral Corso CD, Rutter CE, Park HS et al (2015) Role of chemoradiotherapy in elderly patients with limited small-cell lung cancer. J Clin Oncol 33:4240–4246CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Lu H, Fang L, Wang X et al (2014) A meta-analysis of randomized controlled trials comparing early and late concurrent thoracic radiotherapy with etoposide and cisplatin/carboplatin chemotherapy for limited-disease small-cell lung cancer. Mol Clin Oncol 2:805–810PubMedPubMedCentral Lu H, Fang L, Wang X et al (2014) A meta-analysis of randomized controlled trials comparing early and late concurrent thoracic radiotherapy with etoposide and cisplatin/carboplatin chemotherapy for limited-disease small-cell lung cancer. Mol Clin Oncol 2:805–810PubMedPubMedCentral
22.
Zurück zum Zitat Turrisi AT, Kim K, Blum R et al (1999) Twice daily compared with once-daily thoracic RT in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Eng J Med 340:265–271CrossRef Turrisi AT, Kim K, Blum R et al (1999) Twice daily compared with once-daily thoracic RT in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Eng J Med 340:265–271CrossRef
23.
Zurück zum Zitat Faivre-Finn C, Falk S, Ashcroft et al (2016) Protocol for the CONVERT trial – concurrent once-daily versus twice-daily radiotherapy: an international 2‑arm randomised controlled trial of concurrent chemoradiotherapy comparing twice-daily and once-daily radiotherapy schedules in patients with limited stage small cell lung cancer (LS-SCLC) and good performance status. BMJ Open 6:e009849 doi:10.1136/bmjopen-2015-009849CrossRefPubMedPubMedCentral Faivre-Finn C, Falk S, Ashcroft et al (2016) Protocol for the CONVERT trial – concurrent once-daily versus twice-daily radiotherapy: an international 2‑arm randomised controlled trial of concurrent chemoradiotherapy comparing twice-daily and once-daily radiotherapy schedules in patients with limited stage small cell lung cancer (LS-SCLC) and good performance status. BMJ Open 6:e009849 doi:10.1136/bmjopen-2015-009849CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Slotman BJ, Tinteren H van, Prag JO et al (2015) Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomized controlled trial. Lancet 385:36–42CrossRefPubMed Slotman BJ, Tinteren H van, Prag JO et al (2015) Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomized controlled trial. Lancet 385:36–42CrossRefPubMed
25.
Zurück zum Zitat Auperin A, Arriagada R, Pignon JP et al (1999) Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic cranial irradiation overview collaborative group. N Engl J Med 341:476–484CrossRefPubMed Auperin A, Arriagada R, Pignon JP et al (1999) Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic cranial irradiation overview collaborative group. N Engl J Med 341:476–484CrossRefPubMed
26.
Zurück zum Zitat Nosaki K, Seto T (2015) The role of radiotherapy in the treatment of small-cell lung cancer. Curr Treat Options Oncol 16:56 doi:10.1007/s11864-015-0372-2CrossRefPubMedPubMedCentral Nosaki K, Seto T (2015) The role of radiotherapy in the treatment of small-cell lung cancer. Curr Treat Options Oncol 16:56 doi:10.1007/s11864-015-0372-2CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat Le Pechoux C, Dunant A, Senan S et al (2009) Standard dose versus higher-dose prophylactic cranial irradiation (PCI) in patients with limited-stage small cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 99-01, EORTC 22003-08004, RTOG 0212 and IFCT 99-01): a randomised clinical trial. Lancet Oncol 10:467–474CrossRefPubMed Le Pechoux C, Dunant A, Senan S et al (2009) Standard dose versus higher-dose prophylactic cranial irradiation (PCI) in patients with limited-stage small cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 99-01, EORTC 22003-08004, RTOG 0212 and IFCT 99-01): a randomised clinical trial. Lancet Oncol 10:467–474CrossRefPubMed
28.
Zurück zum Zitat Slotman B, Faivre-Finn C, Kramer G et al (2007) Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med 357:664–672CrossRefPubMed Slotman B, Faivre-Finn C, Kramer G et al (2007) Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med 357:664–672CrossRefPubMed
29.
Zurück zum Zitat Seto T, Takahashi T, Yamanaka T et al (2014) Prophylactic cranial irradiation (PCI) has a detrimental effect on the overall survival (OS) of patients (pts) with extensive disease small cell lung cancer (ED-SCLC): Results of a Japanese randomized phase III trial. J Clin Oncol 32:7503CrossRef Seto T, Takahashi T, Yamanaka T et al (2014) Prophylactic cranial irradiation (PCI) has a detrimental effect on the overall survival (OS) of patients (pts) with extensive disease small cell lung cancer (ED-SCLC): Results of a Japanese randomized phase III trial. J Clin Oncol 32:7503CrossRef
30.
Zurück zum Zitat Yang CF, Chan DY, Speicher PJ et al (2016) Role of adjuvant therapy in population based cohort of patients with early stage small-cell lung cancer. J Clin Oncol 34:1057–1064CrossRefPubMed Yang CF, Chan DY, Speicher PJ et al (2016) Role of adjuvant therapy in population based cohort of patients with early stage small-cell lung cancer. J Clin Oncol 34:1057–1064CrossRefPubMed
31.
Zurück zum Zitat Badzio A, Kurowski K, Karnicka-Mlodkowska H et al (2004) A retrospective comparative study of surgery followed by chemotherapy vs. non-surgical management in limited disease small cell lung cancer. Eur J Cardiothorac Surg 26:183–188CrossRefPubMed Badzio A, Kurowski K, Karnicka-Mlodkowska H et al (2004) A retrospective comparative study of surgery followed by chemotherapy vs. non-surgical management in limited disease small cell lung cancer. Eur J Cardiothorac Surg 26:183–188CrossRefPubMed
Metadaten
Titel
Kleinzelliges Lungenkarzinom
verfasst von
PD Dr. med. M. B. Steins
C. Henkenberens
M. Bremer
M. Thomas
Publikationsdatum
29.06.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
Die Onkologie / Ausgabe 10/2016
Print ISSN: 2731-7226
Elektronische ISSN: 2731-7234
DOI
https://doi.org/10.1007/s00761-016-0073-x

Weitere Artikel der Ausgabe 10/2016

Der Onkologe 10/2016 Zur Ausgabe

Einführung zum Thema

Zervixkarzinom